TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10968096

Group type: EXPERIMENTAL
Intervention: Droperidol 0.625 mg and Metoclopramide 10 mg (Group II)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Droperidol 0.625 mg (Group I)
Number of subjects: 80
Study: 8440364

Group type: EXPERIMENTAL
Intervention: melphalan-prednisone (MP) therapy started at the time of diagnosis
Number of subjects: 50

Group type: COMPARATOR
Intervention: deferred therapy where MP was started at the time of disease progression
Number of subjects: 50
Study: 3532298

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg at night
Number of subjects: 197

Group type: COMPARATOR
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 197
Study: 31373520

Group type: EXPERIMENTAL
Intervention: Guided internet-delivered cognitive behavior therapy (ICBT) for panic disorder
Number of subjects: 143
Study: 27631776

Group type: EXPERIMENTAL
Intervention: Drain
Number of subjects: 469

Group type: COMPARATOR
Intervention: No Drain
Number of subjects: 469
Study: 25888515

Group type: COMPARATOR
Intervention: Cont (no drugs)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Prop (propranolol)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Glyc (glycopyrrolate)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Prop + Glyc
Number of subjects: 9
Study: 23867718

Group type: EXPERIMENTAL
Intervention: Virtual Ophthalmology Clinic (VOC)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 188
Study: 21443960

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02(A) malaria vaccine
Number of subjects: 2022
Study: 19318990

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Group support and attention (GSA)
Number of subjects: 112
Study: 17188040

Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 108

Group type: COMPARATOR
Intervention: SICS
Number of subjects: 108
Study: 15093992

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day) for 30 days
Number of subjects: 43
Study: 11250999

Group type: EXPERIMENTAL
Intervention: High-dose alkylating agents (HDC) with autologous cellular support after doxorubicin-based therapy (AFM)
Number of subjects: 425

Group type: COMPARATOR
Intervention: HER-2 measured by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: HER-2 ECD
Number of subjects: 425
Study: 9385483

Group type: EXPERIMENTAL
Intervention: mibefradil 100 mg
Number of subjects: 239

Group type: COMPARATOR
Intervention: diltiazem CD 360 mg
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: mibefradil
Number of subjects: 239

Group type: COMPARATOR
Intervention: diltiazem CD
Number of subjects: 239
Study: 8487048

Group type: EXPERIMENTAL
Intervention: Standard regimen (S) - six injections of triple intrathecal chemotherapy (TIC) consisting of methotrexate (MTX), hydrocortisone (HC), and cytarabine (ara‐C) during intensification and at every‐8‐week intervals for 17 additional doses.
Number of subjects: 1152

Group type: COMPARATOR
Intervention: Standard and MTX pulses (SAM) - six TICs during intensification, substituted with every‐8‐week pulses of intermediate‐dose parenteral methotrexate (IDM; 1 g/m2) for the 17 maintenance TIC injections, with a low‐dose intrathecal (IT) MTX boost with the first four maintenance IDM pulses.
Number of subjects: 1152
Study: 3440390

Group type: EXPERIMENTAL
Intervention: Population-based screening for hypertension
Number of subjects: 11386

Group type: EXPERIMENTAL
Intervention: Clinic screen for confirmation of elevated BP
Number of subjects: 11386

Group type: EXPERIMENTAL
Intervention: Home BP measurements
Number of subjects: 11386
Study: 2403586

Group type: EXPERIMENTAL
Intervention: Fish oil (2 1-g capsules with each meal for 12 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Olive oil (2 1-g capsules with each meal for 12 weeks)
Number of subjects: 33
Study: 1093506

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride (0.3 mg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Haloperidol (0.25 mg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Haloperidol (0.05 mg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Haloperidol (high dose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 24
Study: 30541021

Group type: EXPERIMENTAL
Intervention: Ustekinumab (UST)
Number of subjects: 44
Study: 27911486

Group type: EXPERIMENTAL
Intervention: Annual PSA tests for 6 years and digital rectal examinations for 4 years (Intervention arm)
Number of subjects: 76383

Group type: COMPARATOR
Intervention: Control arm (no organized screening)
Number of subjects: 76383

Group type: EXPERIMENTAL
Intervention: Annual PSA tests for 6 years (Intervention arm)
Number of subjects: 76383
Study: 25935165

Group type: EXPERIMENTAL
Intervention: Early atrial fibrillation (EAF) within 3 months post-procedure
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Early atrial tachycardia (EAT) within 3 months post-procedure
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: EAF late in the blanking period (after month 2)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Procedure time
Number of subjects: 119
Study: 23094597

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 347

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 347
Study: 22288296

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg/day
Number of subjects: 106

Group type: COMPARATOR
Intervention: Ramipril 2.5 mg/day
Number of subjects: 106

Group type: COMPARATOR
Intervention: Comparison of nebivolol vs ramipril
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 106
Study: 20108648

Group type: EXPERIMENTAL
Intervention: 333 mg acamprosate calcium
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 666 mg acamprosate calcium
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1332 mg acamprosate calcium
Number of subjects: 12
Study: 17007600

Group type: EXPERIMENTAL
Intervention: Personality-targeted interventions (group format; 2 sessions)
Number of subjects: 297

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 297
Study: 15532212

Group type: EXPERIMENTAL
Intervention: Nasal cannula airflow and oximetry monitoring (RDIFlowNPSG)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Nasal cannula airflow and oximetry monitoring (RDIFlowAmbulatory)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Full nocturnal polysomnography (RDIFullNPSG)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Nasal cannula airflow from NPSG
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Nasal cannula airflow from ambulatory study
Number of subjects: 66
Study: 11099991

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) or flutter
Number of subjects: 13858

Group type: COMPARATOR
Intervention: No atrial fibrillation (AF) or flutter
Number of subjects: 13858
Study: 9156638

Group type: EXPERIMENTAL
Intervention: Thymoxamine 0.02%
Number of subjects: 59

Group type: COMPARATOR
Intervention: Acetylcholine 1.0%
Number of subjects: 59

Group type: COMPARATOR
Intervention: Buffered saline solution (BSS)
Number of subjects: 59
Study: 8329904

Group type: EXPERIMENTAL
Intervention: 50 μg fentanyl added to 20 ml of 0.5% bupivacaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 75 μg fentanyl added to 20 ml of 0.5% bupivacaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 100 μg fentanyl added to 20 ml of 0.5% bupivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 80
Study: 3533128

Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg daily
Number of subjects: 11

Group type: COMPARATOR
Intervention: Propranolol (Inderal LA 160 mg daily)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Combined therapy (Nitrendipine and Propranolol)
Number of subjects: 11
Study: 29232323

Group type: EXPERIMENTAL
Intervention: Black participants
Number of subjects: 1070

Group type: COMPARATOR
Intervention: White participants
Number of subjects: 1070
Study: 27436797

Group type: EXPERIMENTAL
Intervention: Data-adaptive selection of adjustment set using cross-validation and TMLE
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Collaborative procedure for estimating known exposure mechanism
Number of subjects: 32
Study: 26338457

Group type: EXPERIMENTAL
Intervention: GnRHAG + E2 (0.075 mg/d)
Number of subjects: 45

Group type: COMPARATOR
Intervention: GnRHAG + PL
Number of subjects: 45
Study: 22988042

Group type: EXPERIMENTAL
Intervention: Comprehensive Health Enhancement Support System + Clinician Report
Number of subjects: 235

Group type: COMPARATOR
Intervention: Comprehensive Health Enhancement Support System‐Only
Number of subjects: 235
Study: 21038017

Group type: EXPERIMENTAL
Intervention: Higher trigeminal component odorants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low, middle, high trigeminal component odorants
Number of subjects: 0
Study: 18429773

Group type: EXPERIMENTAL
Intervention: Olive oil cream (70% lanolin, 30% olive oil)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Water-in-oil emollient cream (Bepanthen)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control group (no specific treatment mentioned)
Number of subjects: 173
Study: 16643541

Group type: EXPERIMENTAL
Intervention: Soy-based formula
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Milk-based formula
Number of subjects: 14

Group type: COMPARATOR
Intervention: Formulas containing only lactose
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Special formulas containing non-milk extrinsic sugar
Number of subjects: 14
Study: 11978257

Group type: EXPERIMENTAL
Intervention: Chart stickers that prompted physicians to calculate a score based on clinical findings and provided management recommendations linked to score totals
Number of subjects: 621

Group type: COMPARATOR
Intervention: Clinical checklist
Number of subjects: 621
Study: 10319057

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 2 mg daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 7611579

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) infusion to reduce mean arterial blood pressure to 50 mmHg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no SNP infusion)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) infusion
Number of subjects: 20
Study: 2229529

Group type: EXPERIMENTAL
Intervention: Oral terbinafine, 125 mg twice daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Griseofulvin, 250 mg twice daily
Number of subjects: 28
Study: 322607

Group type: EXPERIMENTAL
Intervention: Bacampicillin 200 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Bacampicillin 400 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Bacampicillin 800 mg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Ampicillin 500 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Bacampicillin (all doses)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Bacampicillin
Number of subjects: 66
Study: 31542304

Group type: EXPERIMENTAL
Intervention: Galeterone
Number of subjects: 73

Group type: COMPARATOR
Intervention: Enzalutamide
Number of subjects: 73
Study: 30012675

Group type: EXPERIMENTAL
Intervention: ATG (2.5 mg/kg intravenously) followed by pegylated GCSF (6 mg subcutaneously every 2 weeks for 6 doses)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: ATG (2.5 mg/kg) alone
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 27718847

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Chemotherapy (investigator's choice of platinum-based chemotherapy)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 305

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 305
Study: 25201708

Group type: EXPERIMENTAL
Intervention: 4 g/d carnosine for 14 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 23089216

Group type: EXPERIMENTAL
Intervention: Ketoprofen and Symphytum 5CH
Number of subjects: 117

Group type: COMPARATOR
Intervention: Ketoprofen alone
Number of subjects: 117
Study: 20650624

Group type: EXPERIMENTAL
Intervention: 7 weeks ER (CHF‐ER)
Number of subjects: 57

Group type: COMPARATOR
Intervention: 7 weeks usual care (CHF‐UC)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 7 weeks ER (COPD‐ER)
Number of subjects: 57
Study: 17909514

Group type: EXPERIMENTAL
Intervention: Optibond Solo
Number of subjects: 56

Group type: COMPARATOR
Intervention: Delton
Number of subjects: 56

Group type: COMPARATOR
Intervention: Delton Plus
Number of subjects: 56

Group type: COMPARATOR
Intervention: Concise
Number of subjects: 56
Study: 16331772

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: New or worsening back pain
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Moderate to severe back pain
Number of subjects: 471
Study: 11932266

Group type: EXPERIMENTAL
Intervention: Dihydrotestosterone (DHT) gel, administered transdermally for 6 months, dosage varied from 125-250 mg/d
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dihydrotestosterone (DHT) gel
Number of subjects: 120
Study: 9861112

Group type: EXPERIMENTAL
Intervention: Domperidone 20 mg
Number of subjects: 10
Study: 8846803

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg q.i.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diltiazem (90 mg t.i.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diltiazem (mean 329 mg per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diltiazem (180 mg per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose verapamil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium antagonists (combined analysis)
Number of subjects: 0
Study: 2167369

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 323834

Group type: EXPERIMENTAL
Intervention: Increasing doses of frusemide (Group A)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Frusemide in a fixed dose of 80 mg daily and increasing doses of spironolactone (Group B)
Number of subjects: 19
Study: 31667987

Group type: EXPERIMENTAL
Intervention: LUS-guided follow-up (n=61)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Standard follow-up (n=62)
Number of subjects: 123
Study: 28317660

Group type: EXPERIMENTAL
Intervention: Intradermal with DebioJect™ (IDJ)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard intradermal with classical needle (IDS)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intramuscular with classical needle (IM)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: All groups (IDJ, IDS, IM)
Number of subjects: 66
Study: 25290743

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) with music during CWR exercise tests
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (listening to music during CWR exercise tests)
Number of subjects: 39
Study: 24089511

Group type: EXPERIMENTAL
Intervention: GLP‐1 (0.8 pmol/kg ⋅ min) continuous 24‐h infusion (prolonged)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GLP‐1 (0.8 pmol/kg ⋅ min) two 4.5‐h infusions separated by 20 h (intermittent)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GLP‐1 (0.8 pmol/kg ⋅ min) 4.5‐h infusion (acute)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous saline (placebo)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GLP‐1 (0.8 pmol/kg ⋅ min) acute and intermittent regimens
Number of subjects: 10
Study: 22292365

Group type: EXPERIMENTAL
Intervention: Central monitoring method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chart review method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Literature study method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spontaneous reporting method
Number of subjects: 0
Study: 19542037

Group type: EXPERIMENTAL
Intervention: Comprehensive school-based program
Number of subjects: 1714

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 1714
Study: 17540209

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/d)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional treatment for heart failure
Number of subjects: 38
Study: 15376463

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily for 6 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no Orlistat)
Number of subjects: 36
Study: 11136838

Group type: EXPERIMENTAL
Intervention: ABMT arm (high-dose chemotherapy plus autologous bone marrow transplantation)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Control arm (standard chemotherapy)
Number of subjects: 311
Study: 9665112

Group type: EXPERIMENTAL
Intervention: Thrice-yearly deworming with 500 mg mebendazole
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Twice-yearly deworming with 500 mg mebendazole
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 30
Study: 1927238

Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.5 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg) with warning signal
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo with warning signal
Number of subjects: 8
Study: 6749348

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg once daily
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 50 mg once daily
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Chlorothiazide 500 mg twice daily
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Chlorothiazide 500 mg once daily
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Chlorothiazide 1000 mg once daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31972618

Group type: EXPERIMENTAL
Intervention: CAP/CHROMO
Number of subjects: 1905

Group type: COMPARATOR
Intervention: SC
Number of subjects: 1905
Study: 30903410

Group type: EXPERIMENTAL
Intervention: Bone allograft with gentamicin (8 mg gentamicin/gram bone solution for 1 hour)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bone allograft without gentamicin
Number of subjects: 50
Study: 29059253

Group type: EXPERIMENTAL
Intervention: e-POCT
Number of subjects: 3192
Study: 26893605

Group type: EXPERIMENTAL
Intervention: Ready-to-use supplementary food (RUSF)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Corn-soy blend (CSB)
Number of subjects: 84
Study: 25550296

Group type: EXPERIMENTAL
Intervention: Indirect moxibustion for 30 minutes daily, five sessions weekly for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dressing application only
Number of subjects: 30
Study: 22434716

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 217
Study: 20556805

Group type: EXPERIMENTAL
Intervention: Intracoronary bone marrow-derived cell (BMC) transplantation
Number of subjects: 725
Study: 18686554

Group type: EXPERIMENTAL
Intervention: Training health workers using the IMCI module 'Counsel the mother'
Number of subjects: 375

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 375
Study: 15805205

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1000 mg administered intravenously five minutes before skin incision)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (tranexamic acid not administered)
Number of subjects: 21
Study: 12891221

Group type: COMPARATOR
Intervention: Topical diclofenac (65 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral diclofenac (93 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10554529

Group type: EXPERIMENTAL
Intervention: Higher doses of sodium selenite
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9167113

Group type: EXPERIMENTAL
Intervention: Epalrestat (150 mg/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (no epalrestat)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Epa(+) and Epa(-) groups
Number of subjects: 31
Study: 1447639

Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed formula (Nidal HA)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Adapted formula (Nidina)
Number of subjects: 256
Study: 3515950

Group type: EXPERIMENTAL
Intervention: Cefotetan (2 gm single dose)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cefoxitin (three 2 gm doses)
Number of subjects: 36
Study: 30454668

Group type: EXPERIMENTAL
Intervention: NP+FI
Number of subjects: 3816

Group type: COMPARATOR
Intervention: UC
Number of subjects: 3816
Study: 26362564

Group type: EXPERIMENTAL
Intervention: 60 mg dextromethorphan plus 100 mg sitagliptin
Number of subjects: 20

Group type: COMPARATOR
Intervention: 100 mg sitagliptin alone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 24363555

Group type: EXPERIMENTAL
Intervention: Waon therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 22677305

Group type: EXPERIMENTAL
Intervention: Diclofenac-K 12.5 mg liquid capsules
Number of subjects: 42

Group type: COMPARATOR
Intervention: Diclofenac-K 12.5 mg tablets
Number of subjects: 42
Study: 20923065

Group type: EXPERIMENTAL
Intervention: Covering letters signed by three researchers
Number of subjects: 750

Group type: COMPARATOR
Intervention: Covering letters signed by one researcher
Number of subjects: 750
Study: 17875557

Group type: EXPERIMENTAL
Intervention: Balance rehabilitation to improve motor and sensory strategies (Group 1)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Balance rehabilitation to improve motor strategy (Group 2)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Treatments not specifically aimed at improving balance (Group 3)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Activities‐specific Balance Confidence and Dizziness Handicap Inventory (self-administered tests)
Number of subjects: 44